Everything below concerns Pentapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
== Patents == U.S. patent 2,163,754 was issued on June 27, 1939 – Ticket dispensing machine. U.S. patent D132,182 was issued on April 28, 1942 – Design for air conditioning unit. U.S. patent 2,336,735 was issued on December 14, 1943 – Removable cooling units for compartments. U.S. patent 2,337,164 was issued on December 21, 1943 – Means for automatically stopping and starting gas engines. U.S. patent 2,376,968 was issued on May 29, 1945 – Two-cycle gas engine. U.S. patent 2,417,253 was issued on March 11, 1947 – Two-cycle gas engine. U.S. patent 2,475,841 was issued on July 12, 1949 – Automatic refrigeration system for long-haul trucks. U.S. patent 2,475,842 was issued on July 12, 1949 – Starter generator. U.S. patent 2,475,843 was issued on July 12, 1949 – Means operated by a starter generator for cooling a gas engine. U.S. patent 2,477,377 was issued on July 26, 1949 – Means for thermostatically operating gas engines. U.S. patent 2,504,841 was issued on April 18, 1950 – Rotary compressor. U.S. patent 2,509,099 was issued on May 23, 1950 – System for controlling operation of refrigeration units. U.S. patent D159,209 was issued on July 4, 1950 – Design for air conditioning unit. U.S. patent 2,523,273 was issued on September 26, 1950 – Engine actuated ventilating system. U.S. patent 2,526,874 was issued on October 24, 1950 – Apparatus for heating or cooling atmosphere within an enclosure. U.S. patent 2,535,682 was issued on December 26, 1950 – Prefabricated refrigerator construction. U.S. patent 2,581,956 was issued on January 8, 1952 – Refrigeration control device. U.S.
=== 2026 recalls of Semaglutide === In mid August 2026, Dr. Reddy's Laboratories Canada Inc. issued a class 2 recall on its Semaglutide Injection due to affected lots containing a 4 mg pen but is labelled as a 2 mg pen.
== Clinical services == The institution is a specialist hospital covering the major fields of dentistry and oral and maxillofacial medicine. Its clinical departments include cariology and endodontics, periodontics, oral medicine, prosthodontics, implant dentistry, orthodontics, pediatric dentistry, preventive dentistry and general dentistry, as well as several oral and maxillofacial surgical services. Its surgical services include head and neck oncology, trauma and reconstructive surgery, orthognathic and temporomandibular-joint surgery, and cleft lip and palate surgery. Supporting departments include oral pathology, radiology, anesthesia, pharmacy, clinical laboratory services and dental technology. The hospital identifies eight areas as national key clinical specialties: cariology and endodontics, periodontics, oral and maxillofacial surgery, prosthodontics, orthodontics, oral implantology, pediatric dentistry and oral mucosal disease. It also serves as a national standardized residency-training base and is involved in the national qualification examination and examiner training system for stomatology. The hospital records more than one million outpatient and emergency visits annually. Its emergency dentistry department provides 24-hour treatment for conditions including acute dental pain, oral infection, bleeding and dental or maxillofacial trauma.
=== Hydrogen bonding and solubility === Because of the greater electronegativity of oxygen than nitrogen, the carbonyl (C=O) is a stronger dipole than the N–C dipole. The presence of a C=O dipole and, to a lesser extent a N–C dipole, allows amides to act as H-bond acceptors. In primary and secondary amides, the presence of N–H dipoles allows amides to function as H-bond donors as well. Thus amides can participate in hydrogen bonding with water and other protic solvents; the oxygen atom can accept hydrogen bonds from water and the N–H hydrogen atoms can donate H-bonds. As a result of interactions such as these, the water solubility of amides is greater than that of corresponding hydrocarbons. These hydrogen bonds also have an important role in the secondary structure of proteins. The solubilities of amides and esters are roughly comparable. Typically amides are less soluble than comparable amines and carboxylic acids since these compounds can both donate and accept hydrogen bonds. Tertiary amides, with the important exception of N,N-dimethylformamide, exhibit low solubility in water.
Sources: en.wikipedia.org
== Research == The antibacterial effect described above (§ Environmental effects) could be applied against multiresistant biotypes in crop bacterial diseases and bacterial aquaculture diseases. In a glucocorticoid receptor-defective zebrafish mutant (Danio rerio) with reduced exploratory behavior, fluoxetine rescued the normal exploratory behavior. This demonstrates relationships between glucocorticoids, fluoxetine, and exploration in this fish. Fluoxetine has an anti-nematode effect. Choy et al., 1999 found some of this effect is due to interference with certain transmembrane proteins.
== See also == Bush tax cuts – Changes to the United States tax code during the Bush presidency Omnibus spending bill – Type of appropriations bill Tax reform – Method of changing compulsory fees or levies as part of broad economic programmes
=== 2022 medication shortage === In November 2022, Australia's medical regulatory agency, the Therapeutic Goods Administration (TGA) reported that there was a global shortage of the diabetes medication Ozempic. According to the TGA, the rise in demand was caused by an increase in off-label prescription of the drug for weight loss purposes. In December 2022, with the United States experiencing a shortage as well, it was reported that the huge increase in demand for the medicine was caused by a weight loss trend on TikTok, where videos about the drug exceeded 360 million views. Wegovy, a drug that has been specifically approved for treating obesity, also became popular on the platform after Elon Musk credited it for helping him lose weight.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.